452 related articles for article (PubMed ID: 26400188)
1. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
Chen C; Tao C; Liu Z; Lu M; Pan Q; Zheng L; Li Q; Song Z; Fichna J
Phytother Res; 2015 Nov; 29(11):1822-7. PubMed ID: 26400188
[TBL] [Abstract][Full Text] [Related]
2. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effect of Chang'an I Recipe ( I ) on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial.
Tang XD; Lu B; Li ZH; Wei W; Meng LN; Li BS; Tang ZP; Gao R; Wang FY; Lu F; Bian LQ; Zhao YP; Wang P; Zhang YQ
Chin J Integr Med; 2018 Sep; 24(9):645-652. PubMed ID: 27487786
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial.
Li Q; Zhang BP; Huang SG; Ouyang WW; Xie JH; Wen ZH; Yang XB
Trials; 2018 Jul; 19(1):367. PubMed ID: 29996882
[TBL] [Abstract][Full Text] [Related]
6. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
7. Post-marketing Re-evaluation of Tongxiening Granules () in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control Trial.
Tang XD; Zhang SS; Hou XH; Li ZH; Chen SN; Feng PM; Yang XN; Li HZ; Wu JQ; Xia PJ; Yang XJ; Zhou HJ; Wang HY; Ai YW; Li K
Chin J Integr Med; 2019 Dec; 25(12):887-894. PubMed ID: 31292845
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
Leighton MP; Lam C; Mehta S; Spiller RC
Trials; 2013 Jan; 14():10. PubMed ID: 23302220
[TBL] [Abstract][Full Text] [Related]
9. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial.
Abbasnezhad A; Amani R; Hajiani E; Alavinejad P; Cheraghian B; Ghadiri A
Neurogastroenterol Motil; 2016 Oct; 28(10):1533-44. PubMed ID: 27154424
[TBL] [Abstract][Full Text] [Related]
10. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
[TBL] [Abstract][Full Text] [Related]
11. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
12. [Diarrhea-predominant irritable bowel syndrome of spleen deficiency and damp excess treated with fire needling therapy with filiform needle and acupoint application therapy: a randomized controlled trial].
Shi H; Niu Y; Huang Q; Yang ZM; Yang L
Zhongguo Zhen Jiu; 2021 Sep; 41(9):984-90. PubMed ID: 34491647
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
[TBL] [Abstract][Full Text] [Related]
14. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
Tuteja AK; Fang JC; Al-Suqi M; Stoddard GJ; Hale DC
Scand J Gastroenterol; 2012 Oct; 47(10):1159-64. PubMed ID: 22783919
[TBL] [Abstract][Full Text] [Related]
15. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ
Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
[TBL] [Abstract][Full Text] [Related]
18. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.
Lyra A; Hillilä M; Huttunen T; Männikkö S; Taalikka M; Tennilä J; Tarpila A; Lahtinen S; Ouwehand AC; Veijola L
World J Gastroenterol; 2016 Dec; 22(48):10631-10642. PubMed ID: 28082816
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
Choi CH; Jo SY; Park HJ; Chang SK; Byeon JS; Myung SJ
J Clin Gastroenterol; 2011 Sep; 45(8):679-83. PubMed ID: 21301358
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
